Here, we aimed at evaluating the predictive and prognostic values of LAG-3 and PD-L1 as serum biomarkers for HCC patients treated with TACE, and investigating the changes of serum LAG-3 and PD-L1 levels after TACE. This evidence concerns the gene CD274 and hepatocellular carcinoma.